Ocular Therapeutix’s recent quarterly filing highlights progress with AXPAXLI, its intravitreal anti-angiogenic treatment for wet AMD and diabetic retinal diseases, supported by positive Phase 3 trial data aligning with FDA expectations. The firm operates with a robust liquidity position exceeding $598 million but continues to report significant operating losses reflective of ongoing R&D investment. Commercialization readiness hinges on regulatory approvals, manufacturing scale-up, and market acceptance dynamics typical in ophthalmic biotech. Key operational watchpoints include pivotal trial readouts, NDA filing timelines aimed for late 2026, and the company’s ability to sustain funding given high burn rates.